Get the Stockscreener App
1.66
1.07%
-0.018
After Hours:
1.62
-0.04
-2.41%
Lava Therapeutics Nv stock is traded at $1.66, with a volume of 54,568.
It is down -1.07% in the last 24 hours and down -5.14% over the past month.
LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer.
See More
Previous Close:
$1.678
Open:
$1.67
24h Volume:
54,568
Relative Volume:
0.88
Market Cap:
$42.08M
Revenue:
$9.06M
Net Income/Loss:
$-50.39M
P/E Ratio:
-1.0779
EPS:
-1.54
Net Cash Flow:
$5.89M
1W Performance:
+1.84%
1M Performance:
-5.14%
6M Performance:
-50.15%
1Y Performance:
+12.93%
1-Day Range:
$1.58
$1.68
1-Week Range:
$1.58
$1.72
52-Week Range:
$1.131
$6.47
Lava Therapeutics Nv Stock (LVTX) Company Profile
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-25-22 | Initiated | H.C. Wainwright | Buy |
| Apr-19-21 | Initiated | JP Morgan | Overweight |
| Apr-19-21 | Initiated | Jefferies | Buy |
| Apr-19-21 | Initiated | SVB Leerink | Outperform |
Lava Therapeutics Nv Stock (LVTX) Latest News
Xinhua News | Portuguese scientists discover new approach to combat Alzheimer's disease - Xinhua
After the Lykos debacle, what’s next for psychedelic therapies? - Pharmaceutical Technology
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - BioSpace
LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance UK
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - Yahoo Finance UK
LVTXLAVA Therapeutics N.V. Ordinary Shares Latest Stock News & Market Updates - StockTitan
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
LAVA Therapeutics (NASDAQ:LVTX) Given Market Outperform Rating at JMP Securities - Defense World
LAVA Therapeutics (NASDAQ:LVTX) Issues Earnings Results - Defense World
LAVA Therapeutics Faces Financial Hurdles - TipRanks
LAVA Reports Second Quarter 2024 Financial Results and Business Update - GlobeNewswire
LAVA Reports Second Quarter 2024 Financial Results and Business Update - wallstreet:online
LAVA Therapeutics NV expected to post a loss of 36 cents a shareEarnings Preview - XM
LAVA Therapeutics (NASDAQ:LVTX) Stock Price Up 2.3% - Defense World
All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy - Yahoo Finance Australia
LAVA Therapeutics (NASDAQ:LVTX) Shares Down 0.7% - American Banking and Market News
LAVA Therapeutics (NASDAQ:LVTX) Trading Down 0.7% - Defense World
Investors in LAVA Therapeutics (NASDAQ:LVTX) from a year ago are still down 16%, even after 44% gain this past week - Yahoo Lifestyle Australia
LAVA Therapeutics (NASDAQ:LVTX) Receives Buy Rating from HC Wainwright - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com India
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com UK
Macquarie starts Ensign Group stock coverage with outperform rating By Investing.com - Investing.com India
Barclays sets Charles River Labs stock target with Equalweight rating By Investing.com - Investing.com India
Citi reaffirms sell on Dr. Reddy's shares amid acquisition deal By Investing.com - Investing.com
Jefferies sets buy rating on Syndax stock By Investing.com - Investing.com UK
UBS starts Hydro One stock coverage with neutral rating By Investing.com - Investing.com UK
Lava Therapeutics shares hold target with Buy rating - Investing.com India
JPMorgan starts PagerDuty stock with neutral rating amid 'competitive landscape' By Investing.com - Investing.com Australia
Cava group director Bosserman sells over $2.7 million in company stock By Investing.com - Investing.com Canada
Goldman Sachs sets target on Paramount shares, initiates with sell By Investing.com - Investing.com
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com
Transocean adjusts share capital and treasury shares By Investing.com - Investing.com
LAVA Therapeutics Shareholders Approve Key ResolutionsTipRanks.com - TipRanks
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference - GlobeNewswire
Metric Analysis: LAVA Therapeutics NV (LVTX)'s Key Ratios in the Limelight – DWinneX - The Dwinnex
Kayne Anderson BDC stock gets Market Perform from KBW, notes stable industry focus By Investing.com - Investing.com
Biopharma Layoff Tracker 2024: Barinthus, Agilent, BMS and More Cut Staff - BioSpace
Kinsale Capital's president and COO sells shares worth over $579,000 By Investing.com - Investing.com South Africa
LAVA Announces Annual Meeting of Shareholders - GlobeNewswire
LAVA Announces Annual Meeting of Shareholders - Yahoo Finance
BioCardia secures patent for cardiac delivery catheter By Investing.com - Investing.com India
Karyopharm CEO sells shares worth $3,556 By Investing.com - Investing.com
Lava Therapeutics shares hold target with Buy rating By Investing.com - Investing.com Australia
Verano (OTCMKTS:VRNOF) Shares Down 4.3% - Defense World
Revenues Working Against LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Share Price Following 25% Dive - Simply Wall St
Lava Therapeutics Nv Stock (LVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):